Prostate Cancer

Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.

Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug.

Niraparib in combination with abiraterone acetate, and prednisone resulted in a composite response in more than half of all patients.

Use of 18F-rhPSMA-7.3 PET results in post-scan upstaging compared with conventional imaging in patients with prostate cancer recurrence.

Production of lutetium Lu 177 vipivotide tetraxetan and Luthathera have been temporarily suspended due to potential quality issues identified in their manufacturing processes.

The FDA has accepted a supplemental new drug application for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer and granted it priority review.

Results from the phase 3 ARCHES trial confirm the survival benefit of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

During a live virtual event, Matthew B. Rettig, MD, discussed the results of the TITAN trial of apalutamide for patients with metastatic castration-sensitive prostate cancer.

A recent study looked into where time-to-next therapy and overall survival with immune checkpoint inhibitors were longer compared with taxane therapy, in patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed the CARD trial of cabazitaxel and the VISION trial of lutetium-177 for patients with metastatic castration-resistant prostate cancer.

Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.

Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).

A comprehensive review of treatment options for metastatic prostate cancer, including PSMA-targeted therapies.

Scott Tagawa, MD, MS, FACP expands upon prostate-specific membrane antigen (PSMA)-based PET imaging modalities.

A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.

Scott Tagawa, MD, MS, FACP reviews emerging phenotypic biomarker approaches that may complement genomic biomarker testing.

An overview of genomic biomarker testing approaches for patients with prostate cancer.

Scott Tagawa, MD, MS, FACP, comments on some of the clinical factors that impact diagnosis, prognosis, and treatment of prostate cancer.

Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.

Data presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium highlight the inhibitors’ use in combination regimens, other settings, and next-generation agents.

According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.

In an interview with Targeted Oncology, Shawn Dason, MD, discussed existing disparities in prostate cancer, the impact of the COVID-19 pandemic on the issue, and achieving health equity for patients with prostate cancer in the future.

Leuprolide 42 mg injection emulsion for the treatment of adult patients with advanced prostate cancer has launched in the United States.

The FDA recently approved Lu 177 vipivotide tetraxetan for use in patients with metastatic castration-resistant prostate cancer.